IA
NXTC icon

IndexIQ Advisors’s NextCure NXTC Stock Holding History

IndexIQ Advisors’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,516
Closed -$253K – 1446
2021
Q4 		$253K Sell
3,516
-227
-6% -$19K 0.01% 991
2021
Q3 		$303K Buy
3,743
+375
+11% +$32.9K 0.01% 979
2021
Q2 		$325K Sell
3,368
-41
-1% -$4.2K 0.01% 949
2021
Q1 		$410K Buy
+3,409
New +$494K 0.01% 521

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

IndexIQ Advisors's NXTC Position: Q1 2022 in Review

IndexIQ Advisors sold out of NextCure (NXTC) in Q1 2022, closing a stake of 3,516 shares — an estimated $253K sold.

IndexIQ Advisors first reported a position in NXTC in Q1 2021 and held it in 4 quarters. The position peaked at $410K in Q1 2021. 59 funds tracked by Wall St. Rank hold NXTC as of Q1 2022.

  • IndexIQ Advisors reported no remaining NextCure position as of Q1 2022 after selling out during the quarter.
  • IndexIQ Advisors sold 3,516 NextCure shares in Q1 2022, an estimated $253K.
  • IndexIQ Advisors first reported a position in NextCure in Q1 2021 and held it in 4 quarters.
  • IndexIQ Advisors's NextCure position peaked at $410K in Q1 2021.
  • 59 funds tracked by Wall St. Rank held NextCure as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.